News

Thumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.

In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.

In a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.

Georg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.

In a small study, investigators found they could reduce the antiretroviral therapy (ART) dosing to longer durations and the treatment remained safe and efficacious.

New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention

Beatriz Mothe, MD, PhD discusses the Phase 1/2 STRIVE trial of IMC-M113V, a T cell receptor bispecific therapy targeting HIV-infected cells

Joseph Cherabie MD, MSc, explains the importance of how these 2 components go hand-in-hand, and what it means to continue forward in spite of being in an unpredictable time.

Kellie Hawkins, MD discusses the findings along with the challenges of diagnosing Long COVID in people with HIV, emphasizing the need for improved clinical recognition and education.

At CROI 2025, researchers from Université de Montréal discuss how fostemsavir could target residual viral fragments and reduce inflammation.

Texas is experiencing its largest measles outbreak in 30 years and the Centers for Disease Control and Prevention's (CDC) Epidemic Intelligence Service is providing support there. Here is an overview on testing, disease presentation, and vaccination, as well as commentary on the public health impact of vaccine hesitancy, and the unintended consequences of the immunization program’s success.

Nilu Goonetilleke, LLBHons, BScHons, PhD, presents findings showing the bivalent HIVconsvX vaccine targets both Mosaic-1 and Mosaic-2, resulting in broader immune responses.

Nilu Goonetilleke, LLBHons, BScHons, presents findings from the phase 1 study, showing a 50% reduction in T cell response with age, while 85% of participants demonstrated strong immune responses.

Annie Antar, MD, PhD, offers insights around her research on her findings on this subject.

Emblaveo for multidrug-resistant infections, advancing RNA therapies and new vaccine options, Vaxart's oral norovirus vaccine, and synthetic gel for ABSSSI, and more.

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.

The official cause of death is still under investigation by the New Mexico Office of the Medical Investigator, though the individual tested positive for the measles virus.

Katherine L Kahn, MD, discusses the impact of restricted access to Paxlovid on hospitalization and mortality rates in a highly vaccinated population.

Sean Tucker, PhD, highlights effective immune response and mucosal immunity, paving the way for broader applications in viral disease prevention.

InflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost the company some of its data for its investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).

Phase 1b trial data demonstrated immune response, with 85% reduction in viral shedding and robust mucosal immunity in elderly adults.

The Centers for Disease Control and Prevention (CDC) is on the ground in Texas helping the state’s department of health with the outbreak.

Pemivibart (Pemgarda) demonstrated activity against the LP81 variant.

The phase 1/2a trial of BioNTech's BNT165e vaccine, involving nearly 180 participants, faces delays as global malaria control efforts struggle with funding and political uncertainties.

Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).

This is the second installment of a 2-part report on a new guideline on candidiasis from the European Confederation for Medical Mycology (ECMM) highlights selected treatment recommendations.

Sunil Parikh, MD, MPH, discussed how challenges like drug resistance and the limitations of current methods hindered ivermectin’s effectiveness in reducing malaria incidence.

Alan Dunton, MD, director and chief medical advisor, Recce Pharmaceuticals, discusses the company’s novel product, R327G (RECCE 327), and offers insights into its potential indications and clinical trials.

Manjot K Gill, MD, MS, FASRS, FRCS(C), discusses how reduced retinal capillary perfusion may provide insights into Long COVID’s neurological effects and potential treatment approaches.

Twenty organizations asked the high court to consider the federal government’s position on pre-exposure prophylaxis (PrEP) and HIV and hepatitis testing.